Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero

J Pediatr Hematol Oncol. 2021 May 1;43(4):e601-e604. doi: 10.1097/MPH.0000000000001871.


Rituximab is an antibody that binds to B-lymphocytes and is increasingly used during pregnancy. As an immunoglobulin G, it will transfer across the placenta. Previous case reports describe a diversity of clinical presentations in neonates born following rituximab exposure in utero. Our case is the first to offer the long-term experience in the care of an infant with severe neutropenia and prolonged profound hypogammaglobulinemia and class-switching B cell defect after in utero rituximab exposure.

Publication types

  • Case Reports

MeSH terms

  • Agammaglobulinemia / chemically induced*
  • Agammaglobulinemia / immunology
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Female
  • Humans
  • Immune Reconstitution
  • Infant, Newborn
  • Middle Aged
  • Neutropenia / chemically induced*
  • Neutropenia / immunology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Prenatal Exposure Delayed Effects / chemically induced*
  • Prenatal Exposure Delayed Effects / immunology
  • Rituximab / adverse effects*
  • Rituximab / therapeutic use


  • Antineoplastic Agents, Immunological
  • Rituximab